title: The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.
abstract: The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid syndrome, and the efficacy of extended dosing intervals were reviewed. Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons.
authors.affiliation: Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. aklibanski@partners.org
authors.forename: Anne
authors.initials: A
authors.lastname: Klibanski
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
authors.forename: David R
authors.initials: DR
authors.lastname: Clemmons
authors.forename: Annamaria
authors.initials: A
authors.lastname: Colao
authors.forename: Regina S
authors.initials: RS
authors.lastname: Cunningham
authors.forename: Mark E
authors.initials: ME
authors.lastname: Molitch
authors.forename: Aaron I
authors.initials: AI
authors.lastname: Vinik
authors.forename: Daphne T
authors.initials: DT
authors.lastname: Adelman
authors.forename: Karen J P
authors.initials: KJ
authors.lastname: Liebert
mesh_terms: D000172:Acromegaly / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D015282:Octreotide / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide